Promising Cancer Treatments: Targeting Angiogenesis, Drug Resistance, and More

AMG-706 is a potent angiogenesis inhibitor that effectively suppresses vascular formation. (Fig9A)

GSK2126458 and PKI-587 can inhibit tumor progression in nasopharyngeal carcinoma cells. (Fig9C)

Foretinib can overcome non-small cell lung cancer and target resistant mutations. (Fig9D)

PI-103 attenuates PI3K-AKT signaling and induces apoptosis in mouse T-cell lymphoma. (Fig9E)

QL-Xll-47 is a broad-spectrum antibiotic primarily used for the virus causing Gorden's disease and has not been reported in ovarian cancer. (Fig9G)

WZ-1-84 and WH-4-023 have not been reported in the treatment of ovarian cancer. (Fig9H and 9N)

Sunitinib can be used to treat thyroid and deep-seated cancers, and in combination with radiofrequency ablation, it promotes tumor immune therapy for liver cancer. (Fig9I)

TAE684 is used to treat advanced and progressive liver cancer. (Fig9J)

JNK-9L is associated with the progression of endometrial cancer. (Fig9D)

GSK1904529A reverses MRP1-mediated multidrug resistance. (Fig9P)

TAK-715 induces bone marrow cell nuclear apoptosis. (Fig9Q)

Etoposide has moderate cytotoxic activity in untreated metastatic gastric cancer. (Fig9S)

FH535 can inhibit the proliferation and migration of colorectal cancer. (Fig9T)

FK866 inhibits the metastasis of colorectal cancer by reducing cancer-associated fibroblasts. (Fig9U)